Applications · Therapeutic targets
The same design engine, at therapeutic-grade stringency.
Lagomics is not a drug company. We design novel proteins against disease-relevant targets and validate them with quantitative binding data. The design-validate loop that powers our cosmetic actives also addresses therapeutic programs that need characterized candidates early.
We are currently exploring applications in women's health with federal research support. The goal is the same as in cosmetics: a characterized candidate with measured binding and functional activity, not a prediction alone.
If you have a therapeutic target that needs de novo design and rigorous validation, tell us what you want to modulate.